Quick Summary — APUS scores higher on quality with 4.8/10 vs ALVO's 1.8/10. ALVO trades at $3.00 while APUS trades at $1.32. Both analyzed daily using SEC EDGAR data across 13 institutional models.
APUS scores higher with a 4.8/10 quality rating vs ALVO's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $3.00, ALVO trades +74.0% above its Bayesian DCF fair value of $0.78, while APUS at $1.32 trades +71.7% above its estimate of $0.37. ALVO shows a wider gap between price and intrinsic value.
ALVO earns a Quality of Company score of 1.8/10 compared to APUS's 4.8/10. This moderate difference suggests one company has an edge in fundamental quality, though both may offer investment merit depending on valuation. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
Review the value trap analysis for both ALVO and APUS to assess whether apparent undervaluation reflects genuine opportunity or hidden fundamental risk.
Both ALVO and APUS operate in Drug Manufacturers - Specialty & Generic, which has 79 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare ALVO vs APUS differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.